Prepare a development discussion
Clarify the meeting objective, company position and evidence to discuss with an adviser.
RESEARCH WORKSPACE / CANADA
Keep the brief, evidence, questions and decisions connected—from first discussion to adviser handoff.
Use public information and non-confidential working notes. Entries are not sent to Patefacta. Saving uses this browser profile; JSON lets you keep separate copies. This preview has no team accounts or synchronization.
PATEFACTA — PROJECT PREPARATION DRAFT Untitled project User-entered project information. No professional approval or source completeness is implied. PRODUCT AND PROJECT BRIEF name: Not supplied asset: Not supplied ingredient: Not supplied indication: Not supplied population: Not supplied form: Not supplied route: Not supplied objective: Not supplied stage: unspecified meetingPurpose: unspecified targetDate: Not supplied EVIDENCE REGISTER No evidence recorded. This does not establish that evidence is absent or unnecessary. QUESTIONS, COMPANY POSITIONS AND ANSWERS No questions recorded. ACTIONS AND DEPENDENCIES No actions recorded. PUBLIC-PRICE / USER-ASSUMPTION SCENARIOS — 30 DAYS, CAD No scenarios recorded. USER DECISION RECORD No decisions recorded. EXTERNAL GUIDANCE REFERENCES PW-HC-MEETING: Health Canada pre-application and filing guidance https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/management-drug-submissions-applications/pre-application-filing.html Official meeting-purpose, product-information, question and preparation guidance. The appropriate meeting and scientific acceptability require professional review. PW-HC-SBD: Summary Basis of Decision coverage https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/summary-basis-decision.html Historical authorization considerations for selected drugs; this is not universal coverage. PW-HC-HISTORY: Summary Basis of Decision frequently asked questions https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/summary-basis-decision/frequently-asked-questions-summary-basis-decision-project-phase-2.html A historical decision summary is not up-to-date product information. PW-ON-PRICE: Ontario Formulary https://www.formulary.health.gov.on.ca/formulary/ Public drug price and Amount MOH Pays are separate fields. Public prices do not disclose confidential negotiated net prices. SCOPE AND LIMITATIONS Working preparation draft. User-entered facts, answers and review flags are unauthenticated; they do not establish professional approval. This is one local project. No team account, synchronization, notifications, confidential-document service or automatic source refresh is provided. Historical Canadian examples do not establish the pathway, studies, eligibility or evidence requirements for a new asset. Meeting purpose and materials need appropriate expert review. Scenario totals are CAD arithmetic under explicit user assumptions. They do not establish therapeutic equivalence, clinical dosing, net prices, reimbursement, cost-effectiveness or a complete budget-impact analysis. Quantity phases and copied alternatives are user-created planning assumptions. Phase days must cover the full shared period; no dose, titration schedule or purchase-pack rounding is suggested.